Evaluation Of Anti-Proliferative Effects Of Two Hydrazone Derivatives On Breast, -olon And Hepatic -ancer -ells

Cancer is an increasing health issue whose worldwide incidence is about 6 million cases per yearand characterized by unregulated cell proliferation. Despite the advancing researches aboutcancer, there were not efficient strategies for cancer treatment. Therefore, scientists are stilltrying to find new compounds for treatment of this disease. A number of compounds includinghydrazone and ureido derivatives have been increasingly investigated as targets for differentpharmacological activities containing analgesic, anti-inflammation and anticancer. To the best ofour knowledge, there are no study about anti-proliferative as well as apoptotic effects ofcompounds A (1-(4-(3-nitrobenzylidene aminocarbamoyl)phenyl-3-(4-chlorophenyl)urea) and B (1-(4-(3-chlorobenzylidene aminocarbamoyl)phenyl)-3-(4-chlorophenyl)urea ). The anti-proliferativeactivity was measured by MTT assay at 24, 48 and 72 h on MDA-MB-231(human breastadenocarcinoma), HT-29 (human colon adenocarcinoma) and HepG2 (liver hepatocellularcarcinoma) cells. Apoptotic experiments were performed using Annexin V/PI (Roche AppliedScience, USA) and flow cytometry. Our obtained I-50 values (concentration at which 501 inhibitionoccurred) indicated that MDA-MB-231 cell revealed the most sensitivity and 72 h was the mosteffective incubation time for both compounds. In this regard, compound A showed a considerablepotency in inhibition of breast cancer cells growth compared with compound B (I-50 = 1.95±1.09 vs3.48±1.11 μM ) after 72 h treatment. Our flow cytometric results confirmed the cytotoxicity data andexhibited apoptotic effect of both compounds at early and late stages; however, compound A was themost potent one. -onclusion: The results presented here could be used as a starting point for thedevelopment of powerful chemotherapeutic agents to treat breast cancer.